Peptides for Energy: What the Human Data Shows (2026)

"Peptides for energy" is one of the easiest things in this category to sell, because fatigue is universal, subjective, and improves on its own often enough that almost any intervention picks up credit for it.

The compounds sold against it are the mitochondrial ones — MOTS-c, SS-31 (elamipretide), and NAD+ and its precursors, which get grouped in even though NAD+ is not a peptide at all. The pitch is consistent and mechanistically reasonable: mitochondria make cellular energy, these compounds act on mitochondria, therefore more energy.

The honest position: this is the group where the mechanism is most convincing and the human outcome data is weakest. The best-designed trial in the whole category was run in patients with a genuine mitochondrial disease, over 24 weeks, and it did not meet its primary endpoint¹. And one of the most cited findings for the flagship compound points in the opposite direction from the sales pitch — exercise appears to raise the peptide, rather than the peptide raising your capacity to exercise².

SS-31 / Elamipretide — the Best Trial in the Category, and What It Found

Elamipretide (also sold as SS-31) is the most seriously developed compound here, and it deserves credit for that. It targets cardiolipin in the inner mitochondrial membrane, and it has been through a real clinical program in primary mitochondrial myopathy — a genuine disease of the mitochondria, which is the ideal test case if the mechanism is going to show up anywhere.

The program is a useful lesson in reading trials in order. An early randomized dose-escalation study found a signal on the six-minute walk test³, and a later randomized crossover trial in adults with primary mitochondrial myopathy followed⁴. Then came MMPOWER-3: a Phase 3, randomized, double-blind, placebo-controlled trial over 24 weeks. It did not meet its primary endpoints¹. A subsequent post hoc analysis explored whether specific genotypes responded differently⁵ — worth doing, and worth labeling as what it is, which is hypothesis-generating rather than confirmatory.

Sit with the implication. The most rigorous test of a mitochondrial peptide, in the population most likely to respond, at a dose and duration a sponsor chose, did not produce the result. That is not a reason to conclude the compound is inert. It is a strong reason to be skeptical of a vendor promising a healthy person more energy from the same molecule, with no trial, at a dose nobody validated.

MOTS-c — Where the Arrow Points the Wrong Way

MOTS-c is a mitochondrial-derived peptide with genuinely interesting biology, and it is the compound most often sold on the energy claim specifically.

The human evidence is correlational, and it is worth reading carefully. One study found serum MOTS-c concentration correlated positively with lower-body muscle strength — and explicitly was not related to maximal oxygen uptake⁶. That second half matters: VO2max is about as close as physiology gets to a hard measure of aerobic capacity, which is the thing "more energy" is supposed to mean.

More importantly, look at the direction of the relationship in the training literature. Endurance training enhances mitochondrial respiration by promoting MOTS-c secretion². In other words: the training raises the peptide. That is a finding about what your body does when you train, not evidence that injecting the peptide gives you what training gives you. The mechanistic work is real — MOTS-c improves mitochondrial bioenergetic health through defined pathways⁷ — and it is still a mechanism rather than an outcome.

There is no controlled human trial showing that injected MOTS-c makes a healthy person less tired or more capable. We cover the compound in full in MOTS-c and endurance.

NAD+ — Not a Peptide, and the Human Trials Are Sobering

NAD+ gets sold on the same shelf and in the same sentence, so it belongs here even though it is a coenzyme rather than a peptide.

The human trial record for NAD+ precursors is more developed than for anything else in this group, and it is instructive. Nicotinamide riboside did not alter mitochondrial respiration, content or morphology in skeletal muscle in obese, insulin-resistant men⁸ — a direct test of the mechanism the product is sold on, with a null result. A separate randomized trial in healthy obese humans found changes in body composition and skeletal-muscle acetylcarnitine, without the energy outcome the marketing implies⁹.

Raising a molecule in the blood is not the same as changing what a person can do, and the NAD+ literature is one of the clearest demonstrations of that gap available. Our full assessment is in NAD+ injections: the evidence, and the compound most often sold alongside it is covered in 5-amino-1MQ: does it boost NAD?.

What This Costs, and How It Is Priced

The energy peptides are among the more expensively packaged products on the telehealth desks we track, and the pricing frequently obscures the month.

Live Vital repriced NAD+ in August 2026 to a straight $149/month on a three-month $447 protocol — up 80% from the "$83/mo" that used to be a ten-week total divided by three; the divided-by-three pattern still runs across the rest of its bench, with MOTS-c at an advertised $149/mo. ElitePhysiqMD prices MOTS-C at $337.50 a month, the most expensive item on a peptide page whose homepage advertises the category "from $161/mo". RxPepsDirect sells NAD+ at $100 per 1,000 mg vial and never states how long a vial lasts, with a $39 visit fee and $15 shipping on every order, so a monthly cost cannot be derived from the site at all.

Some are clearer. System Labs states the milligrams and names its pharmacy with a street address — 1,000 mg a month — though its $89 first-month rate has a successor price that appears only as a struck-through number. MadeMed publishes its prices but offers no monthly option: the cheapest way in is a single charge for three months, and the injectable requires an IGF-1 blood test you arrange and pay for yourself.

Every figure above, and what commitment each one requires, is on the best NAD+ injection providers board and in the price transparency index.

The GH-Axis Route to the Same Claim

There is a second energy pitch that does not mention mitochondria at all, and it is the one most likely to reach you through a prescriber rather than a vendor.

Sermorelin, ipamorelin and CJC-1295 are sold on a package of outcomes — better sleep, better recovery, more energy — bundled into a monthly subscription. The energy claim is rarely stated as a testable proposition, which is what makes it hard to argue with: it arrives as an implication alongside sleep and body composition, and improvement in any of them gets attributed to the product.

The pooled human data on the endpoint these compounds are working toward does not support it. A systematic review of growth hormone in healthy, athletic participants found increased lean body mass that the reviewers attributed largely to fluid retention, no improvement in strength or exercise capacity, and increased fatigue among the adverse events¹⁰. Fatigue appearing on the harm side of the ledger is not a small detail when the product is sold for energy.

We cover the axis in GH peptides and recovery, the specific stack in CJC-1295 and ipamorelin, and the compliance picture in are GH peptides safe and legal. The sleep half of the same bundle — which has its own controlled human studies, and they are not flattering either — is in peptides for sleep.

The Oral Contender

5-amino-1MQ is the compound most often sold as the oral route to the same outcome, on the theory that it raises NAD+ by inhibiting the enzyme that consumes it. It is worth naming because it is marketed hard and because the reasoning chain is one step longer than the injectables — inhibit an enzyme, raise a coenzyme, improve mitochondrial function, feel more energetic. Each link needs to hold.

We take the chain apart link by link in does 5-amino-1MQ boost NAD?, with the wider assessment in 5-amino-1MQ: the evidence and what users actually report in 5-amino-1MQ results.

The Boring Answer That Actually Has Evidence

It would be dishonest to write a page about fatigue without naming what the evidence actually supports. Sleep, iron and thyroid status, training load, and — where relevant — a medical cause that has not been looked for. Persistent fatigue is a symptom with a differential diagnosis, and the reason that sentence appears in every clinical text and no product page is that it does not sell anything.

If the underlying issue is undiagnosed, no peptide in this category has evidence of fixing it, and the money spent looking for a shortcut is the same money that would have covered the workup.

Bottom Line

The mitochondrial peptides have the most persuasive mechanism story in the whole peptide category, and among the weakest human outcome data.

Elamipretide is the compound that took the mechanism seriously enough to run a Phase 3 trial in the right population — and that trial did not meet its primary endpoints¹. MOTS-c correlates with strength but not with maximal oxygen uptake⁶, and the training literature suggests exercise raises MOTS-c rather than the reverse². NAD+ precursors failed to change mitochondrial respiration, content or morphology in the muscle of the people studied⁸.

That is not a case for concluding these molecules do nothing — the biology is real, and elamipretide's development program is legitimate science. It is a case for not paying $150 to $340 a month for a subjective outcome that no controlled trial has demonstrated in a healthy person. For how each compound grades against human evidence, see SS-31 (elamipretide), what are peptides good for, and the rankings index.